Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 167,82 € (+2.624,35 %). Medianen er 167,82 € (+2.624,35 %).

Køb	4
Behold	2
Sælg	0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

Flora Growth falls sharply after announcement of capital increase

Flora Growth’s stock plunged about 28.4% in after-hours trading after the company announced a guaranteed public offering of only new common shares. R.F. Lafferty & Co. is acting as bookrunner, and the offering is to be made under an already filed S-3 shelf registration. Flora Growth also announced a rename to ZeroStack and said it will in future describe itself as an asset manager focused on decentralized AI. Investors reacted with concerns about dilution; the timing and terms of the issuance remain dependent on market conditions. » Mere på de.investing.com
Flora Growth starts planned public offering of common stock

Flora Growth has announced a placed public offering of its common stock, with R.F. Lafferty & Co. as sole book-running manager. All shares offered are to come from the company’s existing holdings; size and price range were not disclosed. The offering is subject to market conditions and will be made pursuant to a previously filed shelf registration (Form S-3). Flora Growth plans to change its name to ZeroStack and, according to InvestingPro, has more liquid assets than debt but has recently seen dwindling cash reserves and revenue growth while still not yet profitable. » Mere på de.investing.com
Flora Growth reports quarterly loss per share of $9.05, revenue falls 21.8%

Flora Growth reported a loss per share of $9.05 for the quarter ended September 30, 2025 (prior year: -$10.92). Revenue fell to $9.8 million, down 21.81% from $12.5 million in the same quarter a year earlier. » Mere på finanzen.net
Flora Growth publishes financial update via blog and reports multiple capital and governance changes

Flora Growth filed a blog post as Exhibit 99.1 to an 8‑K with the SEC, noting that the full content was not included in the filing and that it contains forward‑looking statements that cite risks such as volatility in cryptocurrency holdings, share price movements, regulatory requirements and access to capital. The company filed a prospectus supplement for an at‑the‑market offering of $3.45 million and continued selling shares under a previously completed prospectus. Flora Growth also announced a planned name change/private placement related to DeFi Development/ZeroStack and reported the death of independent director Harold Wolkin, which temporarily affected Nasdaq governance requirements; the minimum price requirement has since been met. In addition, the company carried out a 1‑for‑39 reverse split and trading was adjusted accordingly. » Mere på de.investing.com
Flora Growth files prospectus supplement for ATM sales of up to $3.45 million

Flora Growth has filed a prospectus supplement for an at-the-market offering with Revere Securities that permits the sale of common stock worth up to $3.45 million. The supplement is related to the S-3 registration; a prior ATM supplement was terminated after sales totaling $129,482. The company reports high cash burn and a 47% stock decline year-to-date. Flora Growth has since regained compliance with the NASDAQ minimum price requirement following a 1:39 reverse split; there was also a board change and planned transactions with DeFi Development/ZeroStack including a contribution in kind of Solana for a convertible note. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde FLORA GROWTH CORP. Aktie en omsætning på 11,97 mio. € og et nettoresultat på -21,57 mio. €

(EUR)	juni 2026	YoY
Omsætning	11,97 mio.	4,67 %
Bruttofortjeneste	1,42 mio.	40,95 %
Nettoresultat	-21,57 mio.	953,95 %
EBITDA	-21,26 mio.	1.086,49 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	3,83 mio. €
Antal aktier	542,54 t
Højeste/laveste i 52 uger	42,64 € - 5,32 €
Udbytte	Nej
Beta	1,90
P/E (PE Ratio)	-0,02
PEG (PEG Ratio)	0,00
K/I (PB Ratio)	1,84
P/S (PS Ratio)	1,39

Virksomhedsprofil

Flora Growth Corp. og dets datterselskaber beskæftiger sig med vækst, dyrkning og udvikling af medicinsk cannabis og medicinske cannabisderivatprodukter til apoteker, lægeklinikker og kosmetikvirksomheder over hele verden. Selskabet dyrker, forarbejder og leverer cannabisolie af medicinsk kvalitet samt cannabisbaserede medicinske og wellnessprodukter; tilbyder hudpleje- og skønhedsprodukter; udvikler plantebaserede og medicinske farmaceutiske produkter, fytoterapeutika og kosttilskud; og designer og markedsfører loungewear fremstillet af stof og materialer baseret på hamp. Selskabet fremstiller, distribuerer og detailsælger også produkter baseret på cannabidiol (CBD), såsom gummibärer, lokalt anvendelige produkter, tinkturer og vapeprodukter; livsstilswellnessprodukter, herunder spiselige produkter, bad og kropspleje, produkter til kæledyr, sportsrestitution m.m.; leverer tilbehør til cannabisforbrug, personlig opbevaring og rejsetilbehør til vape- og tørret urt-kategorierne; og tilbyder juice, eksotiske frugter overtrukket med chokolade og chokoladebarer samt tørrede frugter, bønner og frugtmasse fra amazonasfrugter i supermarkeder, discountbutikker, kaffebarer, restauranter og lufthavne. Derudover beskæftiger selskabet sig med fremstilling, markedsføring og distribution af drikkevarer; fremstilling og salg af produktformuleringer til smertelindring; og udvikling af farmaceutisk cannabinoidformel til forebyggelse af Sars-Cov-2. Selskabet sælger sine produkter under mærkerne JustCBD, Vessel, Mind Naturals, Mambe, Stardog, Tonino Lamborghini og Kalaya. Flora Growth Corp. blev stiftet i 2019 og har hovedkvarter i Toronto, Canada.

Navn	FLORA GROWTH CORP. Aktie
CEO	Daniel Reis-Faria
Hjemsted	Toronto, on Canada
Websted	floragrowth.com
Sektor	Materialer
Branche	Kemikalier
Børsnotering	11.05.2021
Medarbejdere	64